• Clinical
  • All of the VCI criteria rely on clinical evidence of a cognitive impairment syndrome (subdivided as MCI or dementia), clinical evidence of cerebrovascular disease (most commonly, history of stroke or neuroimaging evidence of severe clinically unapparent cerebrovascular disease), and a clinical judgment that the cerebrovascular disease is causing the cognitive impairment. (ahajournals.org)
  • Andreasen N., Minthon L., Davidsson P., Vanmechelen E., Vanderstichele H., Winblad B., and Blennow K. (2001) Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. (springer.com)
  • 1998) High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. (springer.com)
  • patients
  • Since AICD has been found to be elevated in patients suffering from Alzheimer¿s Disease (AD) and may play a role in AD pathology, this study contributes to further insight into the potential role that AICD transcriptional modulation may have with respect to AD development. (nus.edu.sg)